Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru.
Related Resource(s)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202191Date
2018-09Author(s)
Huaman, Moises A.
Henson, David
Rondan, Paola L.
Ticona, Eduardo
Miranda, Gustavo
Kryscio, Richard J.
Mugruza, Raquel
Aranda, Ernesto
Ticona, César
Abarca, Susan
Heredia, Paula
Aguirre, Andrés
Sterling, Timothy R.
Garvy, Beth A.
Fichtenbaum, Carl J.
Metadata
Show full item recordAbstract
Se reportó previamente el incremento sin estimulación de niveles de interferón-gama en sangre, en personas con infección latente de tuberculosis (LTBI), en Estados Unidos, sugiriendo activación inmune mejorada en LTBI. Para investigar esto en un entorno endémico de tuberculosis, se evaluó los niveles de interferón gama in personas con y sin infección latente de tuberculosis en Perú. Se analizó la información de pacientes con y sin un reciente infarto agudo de miocardio tipo 1, seleccionados del Hospital Nacional Dos de Mayo y del Hospital Nacional Edgardo Rebagliati Martins in Lima, Perú, entre julio del 2015 y marzo de 2017. Se les hizo un examen de infección latente de tuberculosis usando el ensayo QuantiFERON® TB Gold In-tube (QFT), los pacientes con QFT positivo se definieron que tenían infección latente de tuberculosis. El interferón-gama no estimulado fue cuantificado vía prueba de ELISA (enzyme-linked immunosorbent assay). Se comparó los niveles de interferón-gama no estimulado entre los grupos con y sin infección latente de tuberculosis. Background: We previously reported increased unstimulated blood levels of interferon-gamma in persons
with latent tuberculosis infection (LTBI) in the United States, suggesting enhanced immune
activation in LTBI. To investigate this further in a TB-endemic setting, we assessed interferon-gamma levels in persons with and without LTBI in Peru.
Methods: We analyzed data from patients with and without a recent type 1 (spontaneous) acute myocardial infarction (AMI) who were enrolled from two public hospital networks in Lima, Peru,
and underwent LTBI testing using the QuantiFERON® TB Gold In-tube (QFT) assay. Participants with a positive QFT test were defined as having LTBI, whereas participants with a
negative QFT test were defined as non-LTBI. Unstimulated interferon-gamma was quantified via enzyme-linked immunosorbent assay in the QFT nil-tube, which does not contain
antigens. We compared unstimulated interferon-gamma levels between LTBI and non-LTBI
groups using the Wilcoxon rank sum test. We used proportional odds modeling for multivariable analysis. Results: Data from 214 participants were included in this analysis. Of those, 120 (56%) had LTBI.
There were no significant differences in age, sex and comorbidities between LTBI and nonLTBI participants, except for recent AMI that was more frequent in LTBI. LTBI participants
had higher unstimulated interferon-gamma levels compared to non-LTBI participants
(median, interquartile range; 14 pg/mL, 6.5–52.8 vs. 6.5 pg/mL, 4.5–15; P<0.01). LTBI
remained associated with higher unstimulated interferon-gamma levels after controlling for
age, sex, recent AMI, history of hypertension, diabetes mellitus, dyslipidemia, end stage
renal disease, malignancy, obesity, and tobacco use (adjusted odds ratio, 2.93; 95% confidence interval, 1.8–4.9). In a sensitivity analysis that excluded participants with AMI, the
association between unstimulated interferon-gamma and LTBI remained present (adjusted
odds ratio; 3.93; 95% confidence interval, 1.9–8.2).
Conclusions: LTBI was associated with higher unstimulated interferon-gamma levels. These data suggest
ongoing immune activation in LTBI.
Notes
El Consejo Editorial es un equipo de expertos en el campo de la revista.
Collections
- Artículos científicos [933]